News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
693,868 Results
Type
Article (41275)
Company Profile (224)
Press Release (652369)
Section
Business (209083)
Career Advice (2040)
Deals (36540)
Drug Delivery (85)
Drug Development (82436)
Employer Resources (170)
FDA (16311)
Job Trends (15302)
News (353489)
Policy (33755)
Tag
Academia (2568)
Africa (770)
Allergies (39)
Alliances (50852)
Alzheimer's disease (1111)
Antibody-drug conjugate (ADC) (49)
Approvals (16253)
Arizona (165)
Artificial intelligence (58)
Asia (39430)
Australia (6280)
Bankruptcy (360)
Best Places to Work (11302)
Biosimilars (58)
C2C Services and Suppliers (79728)
California (822)
Canada (645)
Cancer (181)
Career advice (1710)
CAR-T (34)
Cell therapy (67)
China (50)
Clinical research (64095)
Collaboration (58)
Colorado (34)
Compensation (30)
COVID-19 (2522)
Cystic fibrosis (71)
Diabetes (32)
Diagnostics (5968)
Diversity, equity & inclusion (44)
Drug pricing (53)
Earnings (84430)
Employer resources (144)
Europe (83679)
Events (109721)
FDA (16355)
Florida (106)
Funding (39)
Gene therapy (59)
GLP-1 (492)
Government (4385)
Healthcare (18704)
Hotbed/Location (489810)
Idaho (55)
Illinois (198)
Indiana (108)
Infectious disease (2535)
Inflammatory bowel disease (87)
Interviews (316)
IPO (16391)
Job creations (4042)
Job search strategy (1480)
Kansas (90)
Layoffs (391)
Legal (8275)
Liver cancer (52)
Lung cancer (37)
Maine (47)
Management (54)
Manufacturing (50)
Maryland (253)
Massachusetts (455)
Medical device (13028)
Medtech (13031)
Mergers & acquisitions (19839)
Metabolic disorders (161)
Neuroscience (1194)
New Jersey (62)
New York (83)
NextGen Class of 2024 (6569)
Non-profit (4488)
North Carolina (163)
Obesity (105)
Opinion (184)
Patents (35)
Peanut (35)
Pennsylvania (55)
People (57466)
Phase I (19785)
Phase II (28209)
Phase III (21219)
Podcasts (49)
Policy (37)
Postmarket research (2633)
Preclinical (8453)
Rare diseases (93)
Real estate (6226)
Recruiting (65)
Regulatory (21838)
Reports (32)
Research institute (2347)
Resumes & cover letters (352)
South America (1151)
Startups (3697)
Texas (88)
United States (3032)
Vaccines (425)
Washington State (114)
Weight loss (102)
Date
Today (73)
Last 7 days (499)
Last 30 days (1933)
Last 365 days (38858)
2024 (21950)
2023 (40632)
2022 (51798)
2021 (56332)
2020 (54795)
2019 (47401)
2018 (35773)
2017 (33144)
2016 (32662)
2015 (38617)
2014 (32516)
2013 (27631)
2012 (29729)
2011 (30487)
2010 (28497)
693,868 Results for "ionis pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
Ionis to present at TD Cowen Genetic Medicines & RNA Summit
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a fireside chat at the virtual TD Cowen Genetic Medicines & RNA Summit on Thursday, June 20, 2024.
June 17, 2024
·
1 min read
Business
Ionis reports first quarter 2024 financial results
Ionis Pharmaceuticals, Inc., reported financial results for the first quarter ended March 31, 2024.
May 7, 2024
·
15 min read
Biotech Beach
Ionis Publishes 2023 Corporate Responsibility Report
Ionis Pharmaceuticals, Inc. today published its 2023 Corporate Responsibility Report: Action for a Healthier Future.
April 25, 2024
·
7 min read
Biotech Beach
Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema
Ionis Pharmaceuticals, Inc. announced that it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. under which Otsuka obtains exclusive rights across the Asia-Pacific region for donidalorsen, an investigational RNA-targeted prophylactic medicine for hereditary angioedema.
June 18, 2024
·
5 min read
Biotech Beach
Ionis to host 2024 virtual Annual Meeting of Stockholders
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2024 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 6, 2024.
May 15, 2024
·
2 min read
Drug Development
Ionis to hold donidalorsen Phase 3 data webcast
Ionis Pharmaceuticals, Inc. announced that it will host a live webcast on Friday, May 31th at 8:00 a.m. Eastern Time to discuss the donidalorsen Phase 3 OASIS-HAE and OASISplus study results that will be presented in three late-breaking oral presentations at the 2024 European Academy of Allergy and Clinical Immunology Annual Meeting in Valencia, Spain.
May 28, 2024
·
1 min read
Drug Development
Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for olezarsen, an investigational RNA-targeted medicine for the treatment of adults with familial chylomicronemia syndrome (FCS).
June 25, 2024
·
7 min read
Biotech Beach
Ionis to present at upcoming investor conferences - April 01, 2024
Ionis Pharmaceuticals, Inc. announced that management will participate in fireside chats at the following investor conferences.
April 1, 2024
·
1 min read
Drug Development
Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive results from the Phase 3 OASIS-HAE and OASISplus studies of donidalorsen in patients with hereditary angioedema (HAE).
May 31, 2024
·
12 min read
Business
Ionis to hold first quarter 2024 financial results webcast
Ionis Pharmaceuticals, Inc. announced that it will host a live webcast on Tuesday, May 7th at 11:30 a.m. Eastern Time to discuss its first quarter 2024 financial results.
April 23, 2024
·
1 min read
1 of 69,387
Next
